Aspirin selectively and irreversibly acetylates cyclooxygenase-1 (COX-1), thereby blocking platelet TXA₂ formation and diminishing platelet aggregation mediated by TXA₂ (Fig. 2). This effect is irreversible because platelets are enucleate and unable to resynthesize COX-1. In healthy subjects, even low doses of aspirin (~40 mg daily) cause an almost complete suppression of TXA₂ formation and platelet aggregation throughout the entire platelet lifespan [11]. However, aspirin therapy in DM patients has a high prevalence of hyporesponsiveness or "aspirin resistance" [12] leading to concerns regarding its effectiveness in the primary prevention of CVD. Because clinical studies used different assays, agonists, cutoff values, and cohorts, interpretation of the data and generalization in clinical practice may be difficult.

In patients without prior CVD (primary prevention), indication for antiplatelet therapy remains unclear [13]. In this population, aspirin, the only antithrombotic drug studied in a sufficiently large cohort, shows a statistically significant reduction in the risk for a first MI attack at the expense of increased risk of both gastrointestinal (GI) bleeding and hemorrhagic stroke. However, the clinical benefit of aspirin on MI protection can be different according to concomitant use of standard regimen (e.g., angiotensin-converting enzyme inhibitor and statin). In a recent analysis, the clinical benefit of aspirin was not observed in randomized clinical trials (RCTs) published after 2000 (risk ratio [RR], 0.98; 95% confidence interval [CI], 0.84 to 1.14), in contrast to those published before 2000 (RR, 0.67; 95% CI, 0.56 to 0.81; P_interaction<0.001) [14]. In the meta-analysis by the Antithrombotic Trialists' (ATT) collaboration, aspirin therapy increased major GI and other extracranial bleeds (defined as "a bleed requiring transfusion or resulting in death") (0.10%/year vs. 0.07%/year; RR, 1.54; 95% CI, 1.30 to 1.82; P<0.0001) compared with placebo [15]. When treated with aspirin, the high-risk population would experience 22 more bleeds per 1,000 persons versus 4 more bleeds per 1,000 persons in the low-risk population [16]. A meta-analysis of 16 placebo-controlled RCTs (n=55,462) showed that treatment with aspirin was associated with an increased risk of hemorrhagic stroke by 1.84-fold (P<0.001) [17]. In absolute terms, one could predict 12 incident cases of hemorrhagic stroke per 10,000 patients during chronic aspirin treatment.

During primary CVD prevention that includes subjects with a low risk of developing atherothrombotic events, it is essential to estimate the individual risk-benefit ratio profile, in this case bleeding and hemorrhagic risk [13]. Cardiovascular risk can increase proportionally across primary prevention in young healthy individuals to high-risk individuals and then to secondary prevention (Fig. 3). Aspirin can be recommended for primary cardiovascular prevention based on a threshold risk level, defined as major cardiovascular events (death, MI, or stroke) ≥2 per 100 person-years [13]. An "uncertainty area" at risk levels between 1 and 2 per 100 patient-years should be considered in which the decision to prescribe aspirin is left to the physician's discretion and to the patient's preferences. Moreover, recently the Food and Drug Administration (FDA) has reviewed the available data and does not believe that the current evidence supports the general use of aspirin for primary prevention of a heart attack or stroke. The FDA suggested that it should not be routinely used for primary prevention due to serious risks including increased risk of cerebral and GI bleedings.

Three RCTs conducted specifically in patients with diabetes and six RCTs in which DM patients were subgroups (1% to 22%) failed to show definitive results on the benefit of aspirin in primary CVD prevention (Table 1). A meta-analysis of these nine RCTs found that aspirin therapy was associated with numeric reductions in CAD events (-9%) and cerebrovascular events (-11%) [18]. Based on the overall negative results of these RCTs, it was considered that standard aspirin therapy may be less effective in patients with diabetes than in individuals without diabetes [13]. As such, the current evidence suggests that diabetes should be considered as a unique high-risk entity.

A position statement by the American Diabetes Association (ADA), the American Heart Association, and the American College of Cardiology Foundation recommended that low-dose aspirin (75 to 162 mg daily) for primary prevention is reasonable for DM adults without a previous history of vascular disease who are at increased CVD risk (10-year CVD risk over 10%) without an increased risk for bleeding. This generally includes men over 50 years of age and women over 60 years of age who also have at least one of the following major risk factors: smoking, hypertension, dyslipidemia, family history of premature CVD, and albuminuria [18]. Furthermore, aspirin is no longer recommended for those at low CVD risk (women under 60 years of age and men under 50 years of age with no major CVD risk factors; 10-year CVD risk under 5%). Clinical judgment should be applied for those at intermediate CVD risk (younger patients with one or more risk factors or older patients with no risk factors; those with a 10-year CVD risk of 5% to 10%) until further research is available.

The clinical benefit of aspirin therapy is clearly superior to the risk of major bleeding in the setting of secondary CVD prevention. Aspirin is still the bedrock of antiplatelet therapy for secondary prevention of recurrent ischemic events in patients with atherothrombotic disease, including those with DM [19]. The recommended dose of aspirin for secondary prevention in DM patients with atherosclerotic disease is 75 to 162 mg daily. Low-dose aspirin usage is supported mainly by two large meta-analyses of secondary prevention trials performed by the ATT' collaboration involving 212,000 high-risk patients (with acute or previous vascular disease or some other predisposing condition implying an increased risk of occlusive vascular disease) [15,20]. The results of these meta-analyses showed oral antiplatelet agents, mainly aspirin, to be protective for vascular events in high-risk patients. In particular, the incidence of vascular events was reduced from 22.3% to 18.5% in DM patients (P<0.002) and from 16.4% to 12.8% (P<0.00001) in non-DM patients. Although the overall incidence of vascular events was much higher in DM patients, the benefit of antiplatelet therapy was consistent regardless of DM status [20]. In these trials, low-dose aspirin (75 to 150 mg daily) was found to be at least as effective as higher daily doses, and bleeding complications were reduced with lower doses. The first large-scale RCT comparing high- (300 to 325 mg daily) versus low-dose (75 to 100 mg daily) aspirin therapy was the Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs-Optimal Antiplatelet Strategy for InterventionS 7 (CURRENT-OASIS 7) trial that included ACS patients scheduled to undergo early coronary angiography [21,22]. The rate of 30-day ischemic events did not differ between high-dose versus low-dose aspirin. However, a trend toward higher rates of GI bleeds was observed in the high-dose versus low-dose group (0.38% vs. 0.24%, P=0.051).

Thienopyridines (ticlopidine, clopidogrel, and prasugrel) are nondirect irreversible antagonists of the P2Y₁₂ receptor. Clopidogrel is currently the most commonly prescribed antiplatelet agent. It has similar efficacy and better safety profile compared to ticlopidine. Clopidogrel is a prodrug and needs two-step hepatic conversion to become an active metabolite (Fig. 4) [23]. Numerous data have demonstrated a close relationship between low response to clopidogrel or "clopidogrel resistance" and atherothrombotic events in high-risk patients with acute coronary syndrome (ACS) or those treated with coronary stenting [24]. Because DM itself is an important determinant for clopidogrel responsiveness, an intensified antiplatelet regimen may reduce the risk of "clopidogrel resistance" and consequently the rate of ischemic event occurrence for secondary prevention. Compared with the standard dose of clopidogrel (300 mg loading or 75 mg daily maintenance), high-dose clopidogrel (600 mg loading or 150 mg daily maintenance) strategy is associated with enhanced platelet inhibition and reduced risk for HPR [25], but the high dose strategy can't efficiently overcome the risk of HPR to ADP.

Prasugrel is a third-generation thienopyridine and a prodrug that requires one-step hepatic conversion to its active metabolite to irreversibly inhibit the P2Y₁₂ receptor (Fig. 4). Prasugrel has a more rapid onset of action than clopidogrel and provides greater platelet inhibition because of a more effective conversion into its active metabolite [24]. The Optimizing Antiplatelet Therapy in Diabetes Mellitus-3 (OPTIMUS-3) trial showed that prasugrel (60 mg loading followed by 10 mg maintenance) achieved significantly greater platelet inhibition compared with double-dose clopidogrel (600 mg loading dose followed by 150 mg maintenance) in CAD patients with DM on long-term aspirin treatment, using multiple pharmacodynamics measures [26].

Ticagrelor is a non-thienopyridine, direct-acting, oral antagonist that binds reversibly to the P2Y₁₂ receptor (Fig. 4). The major metabolite of ticagrelor (AR C124910XX), formed by metabolism via the hepatic cytochrome (CYP) 3A4, is as potent as the parent compound ticagrelor. Compared with clopidogrel, ticagrelor results in faster and greater platelet inhibition, with less patient-to-patient variation. In a crossover study including ACS patients with DM (n=30), ticagrelor treatment (90 mg twice daily for 15 days) showed significantly greater platelet inhibition compared with prasugrel treatment (10 mg daily for 15 days) (45.2 vs. 80.8 P2Y₁₂ reaction units measured by the Verify Now P2Y₁₂ assay; P=0.001) [27].

Currently, the ADA recommends the use of clopidogrel in very high-risk DM patients or as an alternative therapy in patients intolerant to aspirin [19]. However, the use of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in DM patients without overt atherosclerotic disease has not been supported by clinical evidence.

The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial has compared clopidogrel (75 mg daily)+low-dose aspirin (75 to 162 mg daily) to placebo+low-dose aspirin in high-risk patients (n=15,603, a median follow-up of 28 months), for primary as well as secondary prevention [28]. In this trial, the rates of major vascular events were not significantly different between the two groups. There was a trend towards higher risk of severe bleeding in the primary prevention group compared with the secondary prevention group. In the primary prevention subgroup with multiple risk factors (n=3,284, 80.8% were diabetics), the rate of the primary endpoint was 6.6% with clopidogrel+aspirin versus 5.5% with placebo+aspirin (P=0.20). In addition, there was a significant increase in cardiovascular death (3.9% in the clopidogrel group vs. 2.2% in the placebo group, P=0.01) and also all-cause mortality in the clopidogrel group (5.4% vs. 3.8, P=0.04) [29]. In addition, the rates of severe and moderate bleedings were 2.0% and 2.2% in the clopidogrel group, and 1.2% and 1.4% in the placebo group, respectively (P=0.07 and P=0.08). There is evidence to suggest that atherosclerotic plaques in DM patients are characterized by increased neovascularization of the vasa vasorum [30], which may be associated with a higher risk of intraplaque hemorrhage with consequent rupture or thrombosis.

Despite improved clinical efficacy of DAPT with COX-1 inhibitor aspirin and a potent P2Y₁₂ receptor inhibitor such as prasugrel and ticagrelor, recurrent ischemic event (~10%/year) and increased risk of bleeding episode observed in a significant percentage of ACS [37,39] suggests a ceiling effect of the current DAPT in attenuating ischemic events and some atherothrombotic events are mediated by other pathway(s). Several drugs with different mechanisms have been proposed for use as an adjunctive treatment to DAPT. Agents that have the potential of this "triple therapy" strategies include GP IIb/IIIa inhibitor, PDE inhibitor, protease-activated receptor-1 (PAR-1) antagonists, and new oral anticoagulants (Fig. 4).

GP IIb/IIIa inhibitors are intravenous antiplatelet agents showing the highest benefit in high-risk patients with ACS undergoing PCI, but questionable efficacy in low- to moderate-risk ACS patients or in those treated with a conservative approach [42].

The benefit of GP IIb/III inhibitor pretreatment during clopidogrel therapy appears more pronounced in high-risk ACS patients, including those with DM undergoing PCI. The Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) trial (n=701) did not show beneficial effects of abciximab over placebo (8.3% vs. 8.6%) on the risk of 1-year death and MI in diabetic patients undergoing elective PCI after high-dose clopidogrel (600 mg) pretreatment (HR, 0.97; 95% CI, 0.58 to 1.62; P=0.91) [43]. The Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) trial (n=2,022) demonstrated a significant reduction of 30-day major adverse cardiac event (MACE) with the use of abciximab versus placebo in patients with NSTE-ACS undergoing PCI on top of 600-mg clopidogrel loading (8.9% vs. 11.9%; OR, 0.75; 95% CI, 0.58 to 0.97; P=0.03) [44], which benefit was restricted to patients with elevated troponin levels (OR, 0.71; 95% CI, 0.54 to 0.95; P=0.02) and was observed across all subgroups, including diabetic patients. The Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY-ACS) trial compared strategy of early (~24 hours before PCI) routine administration with delayed provisional administration of eptifibatide (n=9,492) [45], in which the rate of 30-day death or MI did not differ (11.2% vs. 12.3%; OR, 0.89; 95% CI, 0.79 to 1.01; P=0.08) with the expense of higher risks of bleeding and red-cell transfusion in the early eptifibatide group; absolute reduction of MACE at 96 hours with early eptifibatide treatment was more pronounced in patients with versus without DM (2.1% vs. 0.8%). Additionally, a meta-analysis evaluating the effects of GP IIb/IIIa inhibitors in the setting of primary PCI for STEMI suggested a decrease in mortality, but not in re-infarction in diabetic patients [46].

In the era of potent P2Y₁₂ inhibitor, it may be questionable whether diabetic patients may achieve further clinical benefit from the routine use of GP IIb/IIIa inhibitor in ACS patients. In TRITON, the benefit of prasugrel over clopidogrel on primary ischemic endpoint was irrespective of GP IIb/IIIa inhibitor during the index hospitalization (11% and 16% risk reduction in patients with and without GP IIb/IIIa inhibitor) [37]. In the subset of the PLATO trial planned for an invasive strategy, the clinical benefit of ischemic endpoints with ticagrelor versus clopidogrel was numerically lower in patients receiving GP IIb/IIIa inhibitor (10% and 19% risk reduction in patients with and without GP IIb/IIIa inhibitor) (P_interaction=0.37) [47]. A major concern with routine use of GP IIb/IIIa inhibitor on top of potent P2Y₁₂ inhibitor is the increase in the risk of serious bleeding. The provisional injection of GP IIb/IIIa inhibitor (intravenous or intracoronary) with short-term infusion (~6 hours) in the selected cases as a bridging strategy (e.g., angiographic evidence of massive thrombus, slow or no-reflow, or a thrombotic complication) may be optimal strategy to maximize clinical efficacy and safety during potent P2Y₁₂ inhibitor therapy.

Mammalian phosphodiesterases (PDEs) are the important targets for pharmacologic intervention in the treatment of a number of diseases such as erectile dysfunction, pulmonary hypertension, intermittent claudication, and chronic pulmonary obstructive disease [48]. Therefore, many new PDE inhibitors are being developed for treatment of these disorders. The superfamily of PDEs is comprised of 11 families of enzymes, and individual isozymes modulate distinct regulatory pathways in different cells. For example, PDE5 isozymes are found in platelets, vascular smooth muscle and endothelial cells, with observed high expression in corpus cavernosum and lung. PDE2, PDE3, and PDE5 isozymes are accountable for the majority of platelet PDE activity (>90%) [49]. In platelets, cyclic adenosine 3',5'-monophosphate (cAMP) is hydrolysed by PDE3 and PDE2, whereas cyclic guanosine 3',5'-monophosphate is hydrolysed by PDE5 and PDE2. Dual mechanism with increased production of cAMP (by clopidogrel) and decreased degradation of cAMP (by PDE inhibitor) synergistically enhances the level of intraplatelet vasodilator-stimulated phosphoprotein-phosphorylation and thus stabilize platelet activation. "Triple therapy" with adjunctive PDE3 inhibitor cilostazol to DAPT (aspirin+clopidogrel) significantly enhances platelet inhibition compared with double-dose clopidogrel in high-risk patients (e.g., HPR, AMI, DM, and so on) [50]. On the other hand, other PDE inhibitors pentoxifylline (nonselective) and dipyridamole (PDE5) did not enhance ADP-mediated platelet inhibition similar to cilostazol [51]. The latter finding may be mainly related to different effect of PDE inhibitors on intraplatelet cAMP levels. Contrary to cilostazol, pentoxifylline and dipyridamole have weak effect on intraplatelet cAMP levels, which may be associated with their low PDE3 selectivity.

Cilostazol is a dual inhibitor of PDE3 and adenosine reuptake that may have an important role in reducing ischemic events associated with CAD [50-53]. Cilostazol is a widely used selective and reversible PDE3 inhibitor, which is highly expressed in myocardial and vascular smooth muscle cells (VSMCs) and platelets. It also inhibits adenosine reuptake into erythrocytes, endothelial cells, muscle cells, and platelets, thereby increasing interstitial and circulatory adenosine levels at clinically relevant concentrations (~3 µmol/L). Adenosine activates G-protein-coupled adenosine receptors, possesses a wide range of biological activities and influences cell survival through pre- and post-conditioning processes in experimental studies. In platelets and VSMCs, the interaction of adenosine with Gs-coupled adenosine A₂ receptors results in increased intracellular cAMP. Thus, cilostazol can increase the production and also inhibit the breakdown of cAMP in platelets and VSMCs. The unique feature of cilostazol may contribute to the observed efficacy profile of cilostazol in platelet reactivity and atheroma progression among DM patients. For example, the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) trial compared prevention by cilostazol (100 to 200 mg daily) versus aspirin (81 to 100 mg daily) of progression in carotid intima-media thickness in type 2 diabetic patients during a 2-year observation period [54]. The regression in maximum left and right common carotid artery intima-media thickness was significantly greater with cilostazol compared with aspirin (-0.088±0.260 mm vs. 0.059±0.275 mm, P<0.001; -0.042± 0.274 mm vs. 0.045±0.216 mm, P=0.003). In the Adjunctive Cilostazol versus double-dose ClopidogrEL in Diabetes Mellitus (ACCEL-DM) trial, adjunctive cilostazol to DAPT showed the greater inhibition of platelet aggregation and the lower prevalence of HPR than double-dose clopidogrel in type 2 diabetic patients undergoing PCI [50]. More interestingly, compared with clopidogrel (75 mg daily) on top of aspirin, adjunctive cilostazol (100 mg twice daily) to aspirin showed the similar inhibition of ADP-induced platelet aggregation [52,53]. In addition, the cilostazol treatment achieved the lower level of platelet function after the stimuli with collagen and arachidonic acid compared with the clopidogrel treatment, which implicates the unique character of antiplatelet effect by cilostazol.

The benefit of this triple therapy strategy has been mostly observed in PCI-treated patients, mainly as a reduction in the rates of target lesion revascularization and even in stent thrombosis [55,56,57]. In a recent meta-analysis, adjunctive cilostazol reduced the risk of angiographic restenosis irrespective of stent type (51% and 37% relative reduction after bare-metal stent and drug-eluting stent, respectively) and decreased numerically the risk of stent thrombosis by 43% (95% CI, 0.41 to 1.67), without the increase of major bleeding (OR, 1.00) [55]. The clinical efficacy of cilostazol in ischemic events may be more prominent in the setting of ACS. In a Chinese clinical trial including ACS patients (n=1,212), triple antiplatelet therapy with the addition of 6-month cilostazol after successful PCI was associated with a significantly lower incidence of the primary endpoint (composite of cardiac death, nonfatal MI, stroke, or target vessel revascularization at 1 year) (10.3% vs. 15.1%; HR, 0.65; 95% CI, 0.41 to 0.91; P=0.011), and no differences in the risks of TIMI major or minor bleeding were found (0.2% vs. 0.2%) [56]. Of note, the DM subgroup showed a more pronounced benefit with triple therapy (53% reduction) (Fig. 5). However, the use of cilostazol is limited by the high frequency of side effects (e.g., headache, palpitations, and GI disturbances) and increased risk of withdrawal.

Thrombin is the serine protease enzyme linked between plasmatic and cellular components of the thrombotic process and it plays a crucial role in the platelet activation and coagulation cascade [58]. Platelet PAR-1 and PAR-4 account for the thrombin-mediated signaling in platelets. PAR-1 mediates platelet responses at subnanomolar concentrations of thrombin, whereas PAR-4 mediates platelet activation at higher thrombin concentrations. Activation of either one is sufficient to trigger platelet secretion and aggregation, whereas PAR-1 is likely to be the most important receptor. In addition to platelet-mediated effects and fibrin polymerization during clot generation, thrombin exerts diverse effects on various cells. The PAR-1 receptor is present in platelets, endothelial cells, VSMCs, mononuclear cells, fibroblasts, and cells of atherosclerotic plaque, suggesting a major role in tissue response to injury, angiogenesis, inflammation, and thrombosis. In addition to its role during initial thrombus generation by stimulating platelet aggregation, thrombin that is produced in large quantities following thrombus generation may stimulate the secretion of platelet-derived growth factor and induce angiogenesis. The latter response to thrombin may contribute to vascular remodeling and also restenosis.

Five PAR-1 antagonists have been developed, of which only one drug (vorapaxar) has been investigated in phase III clinical trial and approved for treatment in ACS patients. Vorapaxar is an oral competitive PAR-1 antagonist that blocks thrombin-mediated platelet activation without interfering with thrombin-mediated cleavage of fibrinogen [58]. It is rapidly absorbed (peak level in 60 to 90 minutes), has high bioavailability and a half-life of approximately 311 hours. Following promising findings from early phase clinical investigations, vorapaxar was tested in two large-scale, phase III clinical trials.

In the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial (n= 12,944) [59], the clinical efficacy and safety of vorapaxar (40 mg loading dose and a 2.5 mg daily maintenance dose) versus placebo in addition to standard antiplatelet therapy (96% on aspirin and 91.8% on clopidogrel) was evaluated in patients with NSTE-ACS. Vorapaxar versus placebo treatment was associated with a significant decrease in the composite of cardiovascular death, MI, or stroke at 2 years (14.7% vs.16.4%; HR, 0.89; 95% CI, 0.81 to 0.98; P=0.02), at the expense of the increase in the rate of GUSTO moderate or severe bleeding (7.2% vs. 5.2%; HR, 1.35; 95% CI, 1.16 to 1.58; P<0.001), and a 3-fold increase in intracranial bleeding (1.1% vs. 0.2%, P<0.001). The excess prevalence of intracranial hemorrhage in patients with a history of stroke led to an unplanned safety review, which recommended early termination of this trial.

In the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-TIMI 50 (TRA 2P-TIMI 50) trial (n=26,449) [60], secondary prevention by adjunctive vorapaxar (2.5 mg daily) versus placebo in addition to standard-of-care therapy (58% on DAPT) was assessed among patients with known atherothrombotic disease (a history of MI, ischemic stroke, or peripheral arterial disease). Vorapaxar significantly reduced the primary endpoint (composite of cardiovascular death, MI, or stroke) compared with placebo at 30-month follow-up (9.3% vs. 10.5%; HR, 0.87; 95% CI, 0.80 to 0.94; P<0.001), which was largely driven by a 17% reduction in the MI risk. GUSTO moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (HR, 1.66; 95% CI, 1.43 to 1.93; P<0.001) and intracranial bleeding was a twofold increase by vorapaxar (1.0% vs. 0.5%, P<0.001). Contrary to patients with a history of stroke, patients with previous MI (n=17,779) treated with vorapaxar exhibited a reduction in the primary endpoint at 3-year compared with placebo (8.1% vs. 9.7%; HR, 0.80; 95% CI, 0.72 to 0.89; P<0.0001) [61]. Despite an overall increase in bleeding complications, intracranial bleeding were not significantly higher in the vorapaxar versus placebo group (0.6% vs. 0.4%, P=0.076). The clinical benefit by vorapaxar was even more pronounced after exclusion of elderly patients (>75-year old), individuals with a history of stroke, and those with a low body weight (<60 kg). In diabetic patients with a prior MI (n=3,623) [62], vorapaxar significantly reduced the primary endpoint (11.4% vs.14.3%; HR, 0.73; 95% CI, 0.60 to 0.89; P=0.002) with a number needed to treat to avoid 1 major cardiovascular event of 29. The incidence of GUSTO moderate or severe bleeding was increased with vorapaxar in DM patients (4.4% vs. 2.6%; HR, 1.60; 95% CI, 1.07 to 2.40). However, net clinical outcome integrating these two endpoints (efficacy and safety) was improved with vorapaxar (HR, 0.79; 95% CI, 0.67 to 0.93).

Based on the subanalysis, the FDA approved clinical use of vorapaxar (2.5 mg daily) in addition to standard-of-care therapy (aspirin, clopidogrel, or both) among patients with a history of MI or with peripheral arterial disease. Vorapaxar is contraindicated in patients with a history of stroke, transient ischemic attack, or intracranial hemorrhage, and in those with active pathological bleeding.